Association of reduced immunohistochemical expression of E-cadherin with a poor ovarian cancer prognosis-results of a meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 2003-2007

  Peng, Hong Ling ^a   He, Lei ^a   Zhao, Xia ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

E cadherin; Meta analysis; Ovarian cancer; Overall survival

Indexed keywords

CADHERIN; TUMOR MARKER;

ARTICLE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; META ANALYSIS; METABOLISM; MORTALITY; OVARY TUMOR; PROGNOSIS; SURVIVAL RATE;

CADHERINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84872684228     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.2003     Document Type: Article

References (34)

1. Altundag K, Altundag O, Akyurek S, et al (2006). Inactivation of E-cadherin and less sensitivity of lobular breast carcinoma cells to chemotherapy. Breast, 15, 300.
2. Barraclough H, Simms L, Govindan R (2011). Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol, 6, 978-2.
3. Berx G, van Roy F (2009). Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol, 1, a003129.
4. Blechschmidt K, Sassen S, Schmalfeldt B, et al (2008). The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer, 98, 489-5.
5. Carter JS, Downs LS Jr (2011). Ovarian cancer test and treatment. Female Patient (Parsippany). 36, 30-5.
6. Cho EY, Choi Y, Chae SW, et al (2006). Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int, 56, 62-0.
7. Cisco RM, Ford JM, Norton JA (2008). Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery. Cancer, 113, 1850-6.
8. Daraï E, Scoazec JY, Walker-Combrouze F, et al (1997). Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol, 28, 922-8.
9. Dian D, Brüning A, Mylonas I (2011). E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis. Arch Gynecol Obstet, 284, 437-3.
10. Engelman JA (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer, 9, 550-62.
11. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, et al (2004). Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Onco, 15, 1535-2.
12. Fluge O, Bruland O, Akslen LA, et al (2006). Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid, 16, 161-5.
13. Gadducci A, Ferdeghini M, Cosio S, et al (1999). Preoperative serum E-cadherin assay in patients with ovarian carcinoma. Anticancer Res, 19, 769-2.
14. Haslehurst AM, Koti M, Dharsee M, et al (2012). EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer, 12, 91.
15. Hirohashi S, Kanai Y (2003). Cell adhesion system and human cancer morphogenesis. Cancer Sci, 94, 575-1.
16. Ho CM, Cheng WF, Lin MC, et al (2010). Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. Int J Gynecol Cancer, 20, 1490-7.
17. Huang KJ, Sui LH (2012). The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Med Oncol, 29, 318-3.
18. Janda E, Nevolo M, Lehmann K, et al (2006). Raf plus TGF beta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin. Oncogene, 25, 7117-30.
19. Lau MT, Klausen C, Leung PC (2011). E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression. Oncogene, 30, 2753-66.
20. Mareel M, Berx G, Van Roy F, et al (1996). Cadherin/catenin complex: a target for antiinvasive therapy. J Cell Biochem, 61, 524-0.
21. Martin B, Paesmans M, Mascaux C (2004).Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer, 91, 2018-5.
22. Oza AM, Castonguay V, Tsoref D, et al (2011). Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr Oncol, Suppl 2: S20-7.
23. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-4.
24. Perl AK, Wilgenbus P, Dahl U, et al (1998). A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature, 392, 190-3.
25. Polyak K, Weinberg RA (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer, 9, 265-3.
26. Sawada K, Mitra AK, Radjabi AR, et al (2008). Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res, 68, 2329-39.
27. Shim HS, Yoon BS, Cho NH (2009). Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Hum Pathol, 40, 693-8.
28. St Croix B, Sheehan C, Rak JW, et al (1998). E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol, 142, 557-71.
29. Vincan E, Barker N (2008). The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis, 25, 657-3.
30. Voutilainen KA, Anttila MA, Sillanpää SM, et al (2006). Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol, 59, 460-7.
31. Yamamoto S, Tsuda H, Honda K, et al (2007). Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type. Mod Pathol, 20, 1278-5.
32. Yoshida J, Horiuchi A, Kikuchi N, et al (2009). Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma. Med Mol Morphol, 42, 82-1.
33. Yuecheng Y, Hongmei L, Xiaoyan X (2006). Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis, 23, 65-4.
34. Yu F, Yao H, Zhu P, et al (2007). Let-7 regulates self-renewal and tumorigenicity of breast cancer cells. Cell, 131, 1109-23